Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 10, 2009, Pages 932-940

  Bradbury, Brian D ^a   Do, Thy P ^a   Winkelmayer, Wolfgang C ^b,c   Critchlow, Cathy W ^a   Alan Brookhart, M ^b  

^a AMGEN INC   (United States)

^b HARVARD UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anemia; Confounding by indication; Epoetin alfa; Hemodialysis; Mortality

Indexed keywords

ALBUMIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL PRACTICE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

AGED; ANEMIA; BIOLOGICAL MARKERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); EPOETIN ALFA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 70450180171     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1799     Document Type: Article

References (34)

1. Higgins MR, Grace M, Ulan RA, Silverberg DS, Bettcher KB, Dossetor JB. Anemia in hemodialysis patients. Arch Intern Med 1977; 137: 172-176.
2. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Ann Intern Med 1989; 111: 992-1000.
3. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
4. Ofsthun N, LaBreque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemo-dialysis patients. Kidney Int 2003; 63: 1908-1914. (Pubitemid 36513341)
5. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in HD patients. J Am Soc Nephrol 1999; 10: 610-619. (Pubitemid 29117643)
6. Li S, Collins AJ. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 2004; 65: 626-633. (Pubitemid 38130658)
7. Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68: 2323-2330.
8. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191.
9. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-138.
10. Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 2008; 23: 1682-1689. (Pubitemid 351767748)
11. U.S., Renal Data System: USRDS. 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008.
12. Ebben JP, Gilbertson DG, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events and hospitalizations. Clin J Am Soc Nephrol 2006; 1: 1205-1210.
13. Kausz AT, Solid C, Pereira BJ, Collins AJ, St. Peter WL. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005; 45: 136-147.
14. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72. (Pubitemid 29031210)
15. Roberts TL, Obrador GT, St Peter WL, Pereira BJ, Collins AJ. Relationship among catheter insertions, vascular access infections and anemia management in hemodialysis patients. Kidney Int 2004; 66: 2429-2436.
16. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38: 1251-1263. (Pubitemid 34193111)
17. Cooper BA, Penne EL, Bartlett LH, Pollock CA. Protein malnutrition and hypoalbuminuria as predictors of vascular events and mortality in ESRD. Am J Kidney Dis 2004; 43: 61-66.
18. Besarab A, Boton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 1998; 339: 584-590. (Pubitemid 28385655)
19. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among Epoetin-treated hemodialysis patients. J Clin Epidemiol 2004; 57: 1086-1095. (Pubitemid 39446648)
20. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876. (Pubitemid 39445919)
21. Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and Epoetin alfa among hemodialysis patients. Am J Kidney Dis 2008; 51: 62-70. (Pubitemid 350296516)
22. Brookhart MA, Wang PS, Solomon DH, Schneeweiss S. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology 2006; 17: 1-8. (Pubitemid 43755729)
23. Johnston SC. Combining ecological and individual variables to reduce confounding by indications: case study - subarachnoid hemorrhage treatment. J Clin Epidemiol 2000; 53: 1236-1241.
24. Lacson E Jr, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 2003; 41: 111-124. (Pubitemid 36043358)
25. http://www.kidney.org/PROFESSIONALS/kdoqi/guidelines-updates/doqi-uptoc. html
26. Epogen ® (Epoetin Alfa) Recombinant. Thousand Oaks, CA: Amgen, November, 2007.
27. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996; 91: 444-455. (Pubitemid 126412813)
28. Angrist JD, Imbens GW. Two-stage least squares estimation of average causal effects in models with variable treatment intensity. J Am Stat Assoc 1995; 90: 431-442.
29. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. J Am Med Assoc 1994; 272: 859-966. (Pubitemid 24282095)
30. Brooks JM, Irwin CP, Hunsicker LG, Flanigan MJ, Chrischilles EA, Pendergast JF. Effect of dialysis center profit status on patient survival: a comparison of risk adjustment and instrumental variable approaches. Health Serv Res 2006; 41: 2267-2289.
31. Astor BC, Eustacy JA, Powe NR, Klag MJ, Fink NE, Coresh J. CHOICE Study. Type of vascular access and survival among incident hemodialysis patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol 2005; 16: 449-1455. (Pubitemid 41716530)
32. Greenland S. An introduction to instrumental variables for epidemiologist. Int J Epidemiol 2000; 29: 722-729.
33. Collins AJ, Ebben BS, Gilbertson DT. ESA adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 49: 135-142. 2006.
34. Robins J, Hernan M. Instrumental variable analysis: an epidemiologist's dream? Epidemiology 2006; 17: 360-372.